STN1014003 ophthalmic solution in patients with open-angle glaucoma/ocular hypertension phase III study

Observer -masked comparative study of STN1014003 ophthalmic solution and latanoprost ophthalmic solution in patients with open-angle glaucoma/ocular hypertension and open-label long-term study -Phase III-

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240688

Enrollment

230

Registered

2025-02-18

Start date

2025-03-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

open angle glaucoma (OAG) or ocular hypertension (OHT)

Interventions

Single masked treatment period - STN1014003 Arm:1 drop STN1014003 once daily - Latanoprost Arm:1 drop 0.005% Latanoprost once daily Open-label treatment period - 1 drop STN1014003 once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - 18 years of age or older. - Diagnosis of OAG or OHT in both eyes - Best corrected visual acuity (BCVA) in any eye is 0.20 or better in decimal visual acuity - Willingness and ability to give signed informed consent and follow study instructions

Exclusion criteria

Exclusion criteria: - Clinically significant ocular disease - History of angle closure glaucoma, or narrow angles - Previous glaucoma intraocular surgery - Clinically significant systemic disease - Participation in any investigational study within 30 days prior to screening - Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

Design outcomes

Primary

Measure	Time frame
Mean diurnal IOP at Week 4	—

Contacts

Public ContactKayoko Sakamoto

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026